The human epidermal growth factor receptor 2 (HER2) is the second most important target for systemic breast cancer (BC) therapy after the estrogen receptor. HER2 overexpression is found in 15%-20% of patients with BC. Today, HER2-directed therapies are considered standard of care in the advanced- and early-disease settings.1–3 Trastuzumab when added to chemotherapy has shown improvement in overall survival (OS) in patients with advanced and early HER2-positive BC.

The APHINITY Study was a randomised, double-blind, phase III study comparing the addition of pertuzumab or placebo to adjuvant trastuzumab and chemotherapy in patients with HER2-positive early breast cancer.

The APHINITY trial was supported by F. Hoffmann-La Roche.

 Title of Publication

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up


Martine Piccart ; Marion Procter; Debora Fumagalli; Evandro de Azambuja; Emma Clark; Michael S. Ewer; Eleonora Restuccia; Guy Jerusalem; Susan Dent; Linda Reaby; Herve Bonnefoi; Ian Krop; Tsang-Wu Liu; Tadeusz Pienkowski; Masakazu Toi; Nicholas Wilcken; Michael Andersson; Young-Hyuck Im; Ling Ming Tseng; Hans-Joachim Lueck; Marco Colleoni; Estefania Monturus; Mihaela Sicoe; Sebastien Guillaume; Jose Bines; Richard D. Gelber; Giuseppe Viale; and Christoph Thomssen for the APHINITY Steering Committee and Investigators

Publication Reference

Journal of Clinical Oncology | Volume 39 | Issue 13 | 1448-1457 | 2021